A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer
Eligible for screening study DCP 001
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or firstname.lastname@example.org for additional information.
NRG Oncology GY018 is temporarily being suspended to accrual in response to the COVID-19 pandemic while we consider options to responsibly continue the trial in the context of the current placebo design. Patients who have already consented and/or entered Step 1 registration will be allowed to proceed. Step 1 registration must be completed for all consented patients by 12 Noon ET, Monday, April 6, 2020.